Eli Lilly and Company vs Vertex Pharmaceuticals Incorporated: Examining Key Revenue Metrics

Eli Lilly vs. Vertex: A Decade of Revenue Growth

__timestampEli Lilly and CompanyVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201419615600000580415000
Thursday, January 1, 2015199587000001032336000
Friday, January 1, 2016212221000001702177000
Sunday, January 1, 2017228713000002488652000
Monday, January 1, 2018214933000003047597000
Tuesday, January 1, 2019223195000004162821000
Wednesday, January 1, 2020245398000006205683000
Friday, January 1, 2021283184000007574400000
Saturday, January 1, 2022285414000008930700000
Sunday, January 1, 2023341241000009869200000
Monday, January 1, 20244504270000011020100000
Loading chart...

Infusing magic into the data realm

A Decade of Growth: Eli Lilly vs. Vertex Pharmaceuticals

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's success. Over the past decade, Eli Lilly and Company and Vertex Pharmaceuticals Incorporated have demonstrated remarkable financial trajectories. From 2014 to 2023, Eli Lilly's revenue surged by approximately 74%, reflecting its robust market strategies and innovative product lines. In contrast, Vertex Pharmaceuticals, while starting from a smaller base, achieved an impressive growth of over 160% during the same period, showcasing its rapid expansion and increasing market presence.

Key Insights

  • Eli Lilly: Consistent growth with a peak in 2023, indicating strong market positioning.
  • Vertex Pharmaceuticals: Rapid growth, especially post-2016, highlighting its aggressive market capture.

This comparison not only underscores the dynamic nature of the pharmaceutical sector but also highlights the strategic maneuvers of these industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025